Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 2,3 Dehydrosilybin
2. 2,3-dehydrosilybin
3. Alepa Forte
4. Alepa-forte
5. Ardeyhepan
6. Cefasilymarin
7. Durasilymarin
8. Hepa Loges
9. Hepa Merz Sil
10. Hepa-loges
11. Hepa-merz Sil
12. Hepabesch
13. Hepar Pasc
14. Hepar-pasc
15. Heparsyx
16. Heplant
17. Lagosa
18. Legalon Forte
19. Silibin
20. Silibinin
21. Silibinin A
22. Silibinin B
23. Silybin A
24. Silybin B
25. Silybinin
26. Carsil
27. Karsil
28. Legalon
29. Silimarin
30. Silymarin
1. Silybin A,b (mixture)
2. 802918-57-6
3. Silybin (a+b)
4. (2r,3r)-3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
5. Legalon
6. Silibin
7. Silliver
8. Silybine
9. Silymarin
10. Chembl9509
11. Silibinin A-silibinin B Mixt.
12. Schembl14270800
13. Schembl22398934
14. Hy-n0779a
15. Cs-0138778
16. S0508
17. E80721
18. Silybin (mixture Of Silybin A And B) 100 Microg/ml In Acetonitrile
19. (2r,3r)-2,3-dihydro-3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-hydroxymethyl-2,3-dihydro-1,4-benzodioxin-6-yl]-4h-1-benzopyran-4-one
20. 2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-(3,5,7-trihydroxy-4-oxobenzopyran-2-yl)benzodioxine
| Molecular Weight | 482.4 g/mol |
|---|---|
| Molecular Formula | C25H22O10 |
| XLogP3 | 2.4 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 4 |
| Exact Mass | 482.12129689 g/mol |
| Monoisotopic Mass | 482.12129689 g/mol |
| Topological Polar Surface Area | 155 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 750 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
Antioxidants
Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)
Protective Agents
Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. (See all compounds classified as Protective Agents.)
A - Alimentary tract and metabolism
A05 - Bile and liver therapy
A05B - Liver therapy, lipotropics
A05BA - Liver therapy
A05BA03 - Silymarin
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Indena - Advancing botanical science with a century of innovation, quality, and trusted global expertise.



FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
Indena - Advancing botanical science with a century of innovation, quality, and trusted global expertise.
About the Company : Indena is a global leader in the identification, development, and production of high-quality plant-derived active ingredients for the pharmaceutical and health-food industries. Fou...
About the Company : At Gnosis by Lesaffre, we harness the power of microorganisms to transform compounds into usable nutritional actives, probiotics, and nutritional yeasts that benefit human wellbein...

About the Company : Teva was established in 1901. Our global headquarters are based in Israel. Today we have a portfolio of more than 3,500 medicines, and produce approximately 120 billion tablets and...

About the Company : Yangzhou Gami Biochem Co., Ltd. is one of the leading exporters of CDCA, UDCA from China. We mainly engaged in sales of biochemical products, API, amino acids, plant extracts, food...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Inulin is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.
Lead Product(s): Inulin,Choline,Silymarin
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2017

Lead Product(s) : Inulin,Choline,Silymarin
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Inuline Supplement in Patients With Irritable Bowel Syndrome
Details : Inulin is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
June 02, 2017

Details:
Silimarin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fatty Liver.
Lead Product(s): Silymarin,Phyllanthus Niruri,Choline
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Sponsor: Fiterman Pharma SRL
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 01, 2016

Lead Product(s) : Silymarin,Phyllanthus Niruri,Choline
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Fiterman Pharma SRL
Deal Size : Inapplicable
Deal Type : Inapplicable
Complex Imaging Assessment of Steatosis
Details : Silimarin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fatty Liver.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 01, 2016

Details:
Erlotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Erlotinib,Silymarin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Kosin University Gospel Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2014

Details : Erlotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2014

Details:
Silymarin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Lead Product(s): Silymarin,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Rottapharm Biotech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2013

Lead Product(s) : Silymarin,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Rottapharm Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Details : Silymarin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Legalon (Silibinin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hepatitis C, Chronic.
Lead Product(s): Silymarin,Interferon Alfa-2B,Ribavirin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Legalon
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 07, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Silymarin,Interferon Alfa-2B,Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Ge...
Details : Legalon (Silibinin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hepatitis C, Chronic.
Product Name : Legalon
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Silibinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C.
Lead Product(s): Silymarin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Silymarin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
Details : Silibinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Legalon (Silibinin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C.
Lead Product(s): Silymarin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Legalon
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Azienda Ospedaliera Universitaria Policlinico
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 26, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Silymarin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Azienda Ospedaliera Universitaria Policlinico
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Details : Legalon (Silibinin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C.
Product Name : Legalon
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2012

Details:
Silymarin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C.
Lead Product(s): Silymarin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2010

Lead Product(s) : Silymarin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Silymarin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Silymarin forte
Dosage Form : Capsule
Dosage Strength : 140mg
Packaging :
Approval Date : 26-03-2018
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Carsil® Max
Dosage Form : Capsule
Dosage Strength : 110mg
Packaging :
Approval Date : 29-11-2021
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Carsil® 22.5 mg film-coated tablets
Dosage Form : Film Coated Tablet
Dosage Strength :
Packaging :
Approval Date : 22-12-2023
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Silarsil
Dosage Form : Capsule
Dosage Strength : 140mg
Packaging :
Approval Date : 26-08-2021
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Silarsil
Dosage Form : Capsule
Dosage Strength : 70mg
Packaging :
Approval Date : 26-08-2021
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Lagosa®
Dosage Form : Tablet
Dosage Strength : 150mg
Packaging :
Approval Date : 01-11-2022
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Lagosa®
Dosage Form : Tablet
Dosage Strength : 150mg
Packaging :
Approval Date : 01-11-2022
Application Number :
Regulatory Info :
Registration Country : Moldova

Regulatory Info :
Registration Country : Italy
Brand Name : Silmar
Dosage Form :
Dosage Strength : 30 Cps 200 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Legalon 200
Dosage Form :
Dosage Strength : 30 Bust Grat Eff 200 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Legalon 70
Dosage Form :
Dosage Strength : 40 Cpr Riv 70 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Reply
14 May 2025
Reply
02 Jan 2025
Reply
10 Dec 2024
Reply
11 Nov 2024
Reply
19 Oct 2023
Reply
24 Apr 2023
Reply
05 Apr 2022
Reply
21 Jul 2020
Reply
20 Jul 2020
Reply
04 Dec 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
77
PharmaCompass offers a list of Silymarin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Silymarin manufacturer or Silymarin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Silymarin manufacturer or Silymarin supplier.
PharmaCompass also assists you with knowing the Silymarin API Price utilized in the formulation of products. Silymarin API Price is not always fixed or binding as the Silymarin Price is obtained through a variety of data sources. The Silymarin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Karsil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Karsil, including repackagers and relabelers. The FDA regulates Karsil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Karsil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Karsil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Karsil supplier is an individual or a company that provides Karsil active pharmaceutical ingredient (API) or Karsil finished formulations upon request. The Karsil suppliers may include Karsil API manufacturers, exporters, distributors and traders.
click here to find a list of Karsil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Karsil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Karsil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Karsil GMP manufacturer or Karsil GMP API supplier for your needs.
A Karsil CoA (Certificate of Analysis) is a formal document that attests to Karsil's compliance with Karsil specifications and serves as a tool for batch-level quality control.
Karsil CoA mostly includes findings from lab analyses of a specific batch. For each Karsil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Karsil may be tested according to a variety of international standards, such as European Pharmacopoeia (Karsil EP), Karsil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Karsil USP).